NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
87.33
-0.98 (-1.11%)
At close: 4:02PM EST

87.33 0.00 (0.00%)
After hours: 4:39PM EST

Stock chart is not supported by your current browser
Previous Close88.31
Open88.18
Bid84.00 x 900
Ask89.99 x 1300
Day's Range87.15 - 88.32
52 Week Range72.30 - 94.19
Volume2,289,105
Avg. Volume2,242,263
Market Cap201.724B
Beta (3Y Monthly)0.85
PE Ratio (TTM)15.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.98 (3.34%)
Ex-Dividend Date2018-03-06
1y Target EstN/A
Trade prices are not sourced from all markets
  • Migraine-Focused Biotech Has A Headache On Quarterly Losses
    Investor's Business Daily3 hours ago

    Migraine-Focused Biotech Has A Headache On Quarterly Losses

    Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.

  • Novartis AG (NVS) Not Doing Enough to Attract Smart Money
    Insider Monkey13 hours ago

    Novartis AG (NVS) Not Doing Enough to Attract Smart Money

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]

  • Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
    Market Realistyesterday

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.

  • Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
    Zacks2 days ago

    Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

    We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

  • These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
    Investor's Business Daily2 days ago

    These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece

    Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.

  • Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
    Zacks5 days ago

    Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View

    Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.

  • Reuters6 days ago

    Novartis division Sandoz recalls one lot of blood pressure drug

    Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. The drug is made by China's Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan. A review was extended to other 'sartan' medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

  • Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending September 30, 2018.

  • Mylan’s Major Drivers: Biosimilars and Asset Acquisitions
    Market Realist6 days ago

    Mylan’s Major Drivers: Biosimilars and Asset Acquisitions

    On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.

  • Here's Why PTC Therapeutics Dropped 18% in October
    Motley Fool7 days ago

    Here's Why PTC Therapeutics Dropped 18% in October

    The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.

  • This Rockville biotech is expanding to a new HQ. Here are the details.
    American City Business Journals7 days ago

    This Rockville biotech is expanding to a new HQ. Here are the details.

    The fast-growing company is consolidating into a larger headquarters in Rockville — not far from its current home.

  • Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
    Zacks7 days ago

    Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

    Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.

  • Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript
    Motley Fool8 days ago

    Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending September 30, 2018.

  • What Lies in Store for Ligand (LGND) This Earnings Season?
    Zacks8 days ago

    What Lies in Store for Ligand (LGND) This Earnings Season?

    Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.

  • 4 months after drug approval, Achaogen eyes fire sale
    American City Business Journals9 days ago

    4 months after drug approval, Achaogen eyes fire sale

    The company, which had hired close to 90 people leading up to its first drug approval, has been cutting jobs since the FDA said its antibiotic could be used in one type of infection but not another.

  • Reuters12 days ago

    Novartis abandons effort for U.S. approval of biosimilar rituximab

    Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. The decision comes after the U.S. Food and Drug Administration (FDA) sought additional information to support the company's application for the drug, which is approved already in the EU, Switzerland, Japan and Australia, the company said in a statement. "We are disappointed to have to make this decision and stand behind the safety, efficacy and quality of our medicine," said Stefan Hendriks, global head of biopharmaceuticals at Sandoz.

  • Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
    Zacks12 days ago

    Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

    Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

  • A Look at Merck’s Diabetes and Women’s Health Business
    Market Realist12 days ago

    A Look at Merck’s Diabetes and Women’s Health Business

    Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline. In the US and international markets, Januvia generated revenues of $498 million and $429 million, respectively, reflecting a ~17% YoY decline and a ~45 YoY growth.

  • Gene therapy: CHOP unveils $75M manufacturing facility (Photos)
    American City Business Journals13 days ago

    Gene therapy: CHOP unveils $75M manufacturing facility (Photos)

    Children's Hospital of Philadelphia expects to double its viral vector manufacturing facility, to support cell and gene therapy, in its new space.

  • GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript
    Motley Fool14 days ago

    GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript

    GSK earnings call for the period ending September 30, 2018.

  • Premier Bay Area biotech developer tees up next major project
    American City Business Journals14 days ago

    Premier Bay Area biotech developer tees up next major project

    The developer behind some of the Bay Area's largest biotech and life sciences campuses is poised to begin construction on another on the Peninsula, which could become the next big biotech hub.

  • Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
    Zacks14 days ago

    Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag

    Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.

  • Reuters14 days ago

    FDA approves Novartis' copy of AbbVie bestseller Humira

    The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday. Although approved, Novartis' Sandoz unit can only begin U.S. sales of Humira's biosimilar in 2023, according to a licensing agreement sealed with AbbVie this month. The biosimilar, Hyrimoz, is approved https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071lbl.pdf for treating several diseases, including rheumatoid arthritis, the FDA said.

  • Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View
    Zacks14 days ago

    Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View

    Amgen (AMGN) beats estimates for both earnings and sales in Q3 and raises guidance for the full year

  • Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line
    Zacks14 days ago

    Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line

    Glaxo beat earnings estimates while sales were in-line in the third quarter of 2018.